Latest Conference Articles

March 25th 2021, 8:15pm

European Lung Cancer Congress

First-line treatment with camrelizumab, an investigational PD-1 inhibitor, plus chemotherapy induced robust and durable clinical responses in patients with advanced squamous non–small cell lung cancer.

March 25th 2021, 6:58pm

European Lung Cancer Congress

The fatty acid synthase inhibition caused by AZ12756122 could represent a promising therapeutic alternative to overcome resistance to EGFR TKIs because of the synergistic interaction that it has with osimertinib and its ability to reduce cancer stem cell properties in EGFR-mutant non–small cell lung cancer cell models.

March 25th 2021, 6:48pm

European Lung Cancer Congress

The frontline combination of nivolumab and ipilimumab plus 2 cycles of chemotherapy demonstrated an improvement in overall survival vs chemotherapy alone in patients with advanced non–small cell lung cancer regardless of tumor mutational burden status in the tissue or blood.

March 24th 2021, 7:55pm

SGO Annual Meeting

Dostarlimab demonstrated durable antitumor activity in patients with mismatch repair deficient and MMR proficient endometrial cancer, regardless of investigator assessment or blinded independent central review and immune-related RECIST or RECIST v1.1 criteria.

March 24th 2021, 3:00pm

School of Gastrointestinal Oncology

Racial disparities affecting all aspects of patient care are a major issue across cancer types, including for patients with gastrointestinal cancers.

March 23rd 2021, 7:15pm

School of Gastrointestinal Oncology

Michael A. Choti, MD, discusses challenging treatment decisions in patients with neuroendocrine tumors.

March 22nd 2021, 9:56pm

SGO Annual Meeting

Olaparib, when used in patients with platinum-sensitive relapsed ovarian cancer who had a known BRCA mutation and homologous recombination deficiency status, demonstrated adverse effects that proved to be consistent with the established safety profile of the PARP inhibitor.

March 20th 2021, 2:45am

SGO Annual Meeting

The combination of pembrolizumab and lenvatinib improved progression-free and overall survival, as well as response rates, compared with chemotherapy in patients with advanced endometrial cancer who received prior platinum-based chemotherapy, irrespective of mismatch repair status, according to phase 3 findings of the Study-309/KEYNOTE-775 trial.

March 17th 2021, 9:08pm

EBMT Meeting

Navneet Majhail, MD, MS, discusses the importance of utilizing social media in oncology.

March 17th 2021, 9:04pm

EBMT Meeting

Corey S. Cutler, MD, MPH, FRCPC, discusses the toxicity profile of belumosudil in patients with chronic graft-versus-host disease.

March 16th 2021, 10:15pm

EBMT Meeting

Corey S. Cutler, MD, MPH, FRCPC, discusses ​the efficacy results of the ongoing phase 2 ROCKstar trial in patients with chronic graft-versus-host disease.

March 16th 2021, 10:12pm

EBMT Meeting

Sergio A. Giralt, MD, discusses the potential utility of omidubicel in hematologic malignancies.

March 16th 2021, 8:15pm

The MASP-2 inhibitor narsoplimab demonstrated high response rates and a significant improvement in laboratory markers and organ function irrespective of subgroup in adult patients with high-risk hematopoietic stem cell transplant–associated thrombotic microangiopathy.

March 16th 2021, 7:13pm

EBMT Meeting

Lisocabtagene maraleucel was successfully administered in patients with relapsed/refractory aggressive large B-cell lymphoma who were at nonuniversity medical centers in both the outpatient and inpatient settings through the use of standard operating procedures and multidisciplinary teams

March 16th 2021, 6:24pm

EBMT Meeting

Ruxolitinib has demonstrated sustained efficacy with a lower probability of progression or additional systemic therapeutics in patients with steroid-refractory acute graft-versus-host disease.

March 16th 2021, 2:00pm

The engineered cord endothelial cell product AB-205 showed an encouraging safety profile along with robust effects in eliminating oral/gastrointestinal severe regimen-related toxicities in patients with systemic lymphoma undergoing high-dose therapy and autologous hematopoietic stem cell transplantation.

March 16th 2021, 1:26am

HCC-TAG Conference

Anjana Pillai, MD, discusses sequential treatment in hepatocellular carcinoma.

March 15th 2021, 10:10pm

EBMT Meeting

Axicabtagene ciloleucel elicited a high objective response rate of 85%, with a complete response rate of 74% when used as a first-line therapy in patients with high-risk large B-cell lymphoma.

March 15th 2021, 9:55pm

EBMT Meeting

A risk-adapted CD19 CAR T-cell therapy dosing approach allowed pediatric patients with relapsed/refractory acute lymphocytic leukemia to maintain a high rate of remission, while reducing the risk of severe toxicities among those with a high initial disease burden

March 15th 2021, 9:06pm

EBMT Meeting

Nicolaus Kröger, MD, discusses the long-term results of a phase 2 study in multiple myeloma.